https://www.thebodypro.com/article/top-tango-two-drug-antiretroviral
HIV Treatment StrategiesFeatures

TANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the Year

#2 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

Two-Drug TANGO photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    GEMINI study results: IDWeek 2019. (2019). "Durable efficacy of two-drug regimen (2DR) of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection at 96 weeks: subgroup analyses in the GEMINI studies." eventscribe.com/2019/IDWeek/fsPopup.asp?Mode=presInfo&PresentationID=582745

    TANGO study results: 10th IAS Conference on HIV Science. (2019). "Switching to DTG + 3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)." programme.ias2019.org/Abstract/Abstract/4903

    TANGO subgroup analysis: 17th European AIDS Conference. (2019). "Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study." professionalabstracts.com/eacs2019/iplanner/#/presentation/285

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.